Adhering to current clinical guidance supports evidence-based assessment, informs decision-making, and helps reduce complications in patients with confirmed or suspected renal cell carcinoma. Ongoing review of recommendations and guidance enables clinicians to improve evaluation and management, which supports better patient outcomes.
Today's rundown features clinical guidelines and consensus statements that focus on or are related to renal cell carcinoma. The following rundown represents current clinical guidance from international societies published within the last ten years.
Current Renal Cell Carcinoma Guidance
- Use of Molecular Imaging for Renal Mass Characterization
- Society of Nuclear Medicine and Molecular Imaging (SNMMI) / European Association of Nuclear Medicine (EANM) / American College of Nuclear Medicine (ACNM), October 2025
- Renal Cell Carcinoma
- European Association of Urology (EAU), March 2025
- Management of Non-Clear Cell Renal Cell Carcinoma
- Canadian Urological Association (CUA), November 2024
- Diagnosis, Treatment and Follow-Up of Renal Cell Carcinoma
- European Society for Medical Oncology (ESMO), May 2024
- Management of Metastatic Renal Clear Cell Cancer
- American Society of Clinical Oncology (ASCO), October 2023
- Adjuvant Therapy for Renal Cell Carcinoma
- Canadian Urological Association (CUA), May 2023
- Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow Up
- American Urological Association (AUA), April 2021
- Immunotherapy for the Treatment of Advanced Renal Cell Carcinoma
- Society for Immunotherapy of Cancer (SITC), December 2019
- Renal Mass and Localized Renal Cancer
- American Urological Association (AUA), September 2017
- Management of Small Renal Masses
- American Society of Clinical Oncology (ASCO), January 2017
Check out other clinical guidelines and sign up for alerts to stay informed on the latest published guidelines and insights.
Copyright © 2026 Guideline Central, all rights reserved.